• $11.4M
    Market Cap
  • N/A
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
4,215
N/A
Cost of Revenue
1,873
N/A
Gross Profit
2,342
N/A
Sales and Marketing Expense
147,694
N/A
Research and Development Expense
0
N/A
Depreciation and Amortization Expense
300,000
N/A
Total Operating Expenses
5.9M
N/A
Operating Profit
-5.9M
N/A
Interest Income
1,000
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
1,000
N/A
Total Nonoperating Income and Expense
-343,166
N/A
Income before Taxes
-5.9M
N/A
Income Taxes
0
N/A
Extraordinary Items
N/A
N/A
Net Income
N/A
N/A
Net Income from Continuing Operations Applicable to Common
N/A
N/A
Basic EPS and Net Income
-0.46
N/A
Diluted EPS and Net Income
-0.46
N/A
Basic Weighted Average Shares
13.6M
N/A
Diluted Weighted Average Shares
13.6M
N/A
Balance Sheet
Cash and Cash Equivalents
2.2M
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
2.2M
N/A
Total Current Assets
2.3M
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
764,308
N/A
Total Assets
2.3M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
25,000
N/A
Total Current Liabilities
176,844
N/A
Total Long-Term Debt
58,650
N/A
Total Long-Term Liabilities
58,650
N/A
Total Liabilities
235,494
N/A
Retained Earnings
-7.1M
N/A
Total Stockholders Equity
2.1M
N/A
Total Shares Outstanding
14.8M
N/A
Cash Flow
Cash from Operating Activities
-1.7M
N/A
Capital Expenditures
N/A
N/A
Cash from Investing Activities
N/A
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
3.4M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow